Behavioural phenotyping of male growth hormone-releasing hormone (GHRH) knockout mice

Growth Hormone and IGF Research

Volumn 24, Issue 5, 2014, Pages 192-197

  Leone, Sheila ^a   Shohreh, Rugia ^a   Manippa, Fabio ^a   Recinella, Lucia ^a   Ferrante, Claudio ^a   Orlando, Giustino ^a   Salvatori, Roberto ^b   Vacca, Michele ^a   Brunetti, Luigi ^a  

^a UNIVERSITY OF CHIETI   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anxiety; Depression; Growth hormone releasing hormone knockout; Norepinephrine; Thyrotropin releasing hormone

Indexed keywords

DOPAMINE; GROWTH HORMONE RELEASING FACTOR; NORADRENALIN; PROTIRELIN; SEROTONIN;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY DISORDER; ARTICLE; BRAIN FUNCTION; BRAIN LEVEL; CONTROLLED STUDY; DEPRESSION; ELEVATED PLUS MAZE TEST; EXPERIMENTAL BEHAVIORAL TEST; FORCED SWIM TEST; GENE; GENE EXPRESSION; GHRH GENE; GROWTH HORMONE DEFICIENCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HYPOTHALAMUS; LIGHT DARK EXPLORATION; LOCOMOTION; MALE; MOUSE; NEUROCHEMISTRY; NONHUMAN; OPEN FIELD TEST; PHENOTYPE; PHYSICAL ACTIVITY; PREFRONTAL CORTEX; PROTEIN ANALYSIS; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TAIL SUSPENSION TEST; ADAPTIVE BEHAVIOR; ANIMAL; ANXIETY; BRAIN; EXPLORATORY BEHAVIOR; GENETICS; KNOCKOUT MOUSE; MAZE TEST; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PHYSIOLOGY;

ADAPTATION, PSYCHOLOGICAL; ANIMALS; ANXIETY; BEHAVIOR, ANIMAL; BRAIN; EXPLORATORY BEHAVIOR; GROWTH HORMONE-RELEASING HORMONE; MALE; MAZE LEARNING; MICE; MICE, KNOCKOUT; MOTOR ACTIVITY; NOREPINEPHRINE; PHENOTYPE; STRESS, PSYCHOLOGICAL; THYROTROPIN-RELEASING HORMONE;

EID: 84908031604     PISSN: 10966374     EISSN: 15322238     Source Type: Journal    
DOI: 10.1016/j.ghir.2014.06.004     Document Type: Article

References (42)

1. Arwert L.I., Deijen J.B., Müller M., Drent M.L. Long-term growth hormone treatment preserves GH-induced memory and mood improvements: a 10-year follow-up study in GH-deficient adult men. Horm. Behav. 2005, 47:343-349.
2. Engin E., Stellbrink J., Treit D., Dickson C.T. Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: behavioral and neurophysiological evidence. Neuroscience 2008, 157:666-676.
3. Engin E., Treit D. Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors. Psychopharmacology (Berl) 2009, 206:281-289.
4. Vécsei L., Bollók I., Telegdy G. Comparative studies with cyclic and linear somatostatin on active avoidance behaviour and open-field activity in rats. Acta Physiol. Hung. 1983, 61:43-49.
5. Telegdy G., Schally A.V. Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice. Behav. Brain Res. 2012, 233:232-236.
6. Alba M., Salvatori R. A mouse with targeted ablation of the growth hormone-releasing hormone gene: a new model of isolated growth hormone deficiency. Endocrinology 2004, 145:4134-4143.
7. Sagazio A., Shohreh R., Salvatori R. Effects of GH deficiency and GH replacement on inter-male aggressiveness in mice. Growth Horm. IGF Res. 2011, 21:76-80.
8. McIlwain K.L., Merriweather M.Y., Yuva-Paylor L.A., Paylor R. The use of behavioral test batteries: effects of training history. Physiol. Behav. 2001, 73:705-717.
9. Paylor R., Spencer C.M., Yuva-Paylor L.A., Pieke-Dahl S. The use of behavioral test batteries, II: effect of test interval. Physiol. Behav. 2006, 87:95-102.
10. Takao K., Miyakawa T. Light/dark transition test for mice. J. Vis. Exp. 2006, 13:104.
11. Pellow S., Chopin P., File S.E., Briley M. Validation of open: closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Methods 1985, 14:149-167.
12. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
13. Taltavull J.F., Chefer V.I., Shippenberg T.S., Kiyatkin E.A. Severe brain hypothermia as a factor underlying behavioral immobility during cold-water forced swim. Brain Res. 2003, 975:224-247.
14. Cryan J.F., Markou A., Lucki I. Assessing antidepressant activity in rodents: recent developments and future needs. Trends Pharmacol. Sci. 2002, 23:238-245.
15. Livak J.K., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 2001, 25:402-408.
16. Brunetti L., Orlando G., Ferrante C., et al. Orexigenic effects of omentin-1 related to decreased CART and CRH gene expression and increased norepinephrine synthesis and release in the hypothalamus. Peptides 2013, 44:66-74.
17. Tanaka M., Schally A.V., Telegdy G. Neurotransmission of the antidepressant-like effects of the growth hormone-releasing hormone antagonist MZ-4-71. Behav. Brain Res. 2012, 228:388-391.
18. Steru L., Chermat R., Thierry B., et al. The automated Tail Suspension Test: a computerized device which differentiates psychotropic drugs. Prog. Neuropsychopharmacol. Biol. Psychiatry 1987, 11:659-671.
19. Prodam F., Caputo M., Belcastro S., et al. Quality of life, mood disturbances and psychological parameters in adult patients with GH deficiency. Panminerva Med. 2012, 54:323-331.
20. Kokshoorn N.E., Biermasz N.R., Roelfsema F., Smit J.W., Pereira A.M., Romijn J.A. GH replacement therapy in elderly GH-deficient patients: a systematic review. Eur. J. Endocrinol. 2011, 164:657-665.
21. Nillni E.A., Sevarino K.A. The biology of pro-thyrotropin-releasing hormone-derived peptides. Endocr. Rev. 1999, 20:599-648.
22. Gary K.A., Sevarino K.A., Yarbrough G.C., Prange A.J., Winokur A. The thyrotropin-releasing hormone (TRH) hypothesis of homeostatic regulation: implications for TRH-based therapeutics. J. Pharmacol. Exp. Ther. 2003, 305:410-416.
23. Gutiérrez-Mariscal M., de Gortari P., López-Rubalcava C., Martínez A., Joseph-Bravo P. Analysis of the anxiolytic-like effect of TRH and the response of amygdalar TRHergic neurons in anxiety. Psychoneuroendocrinology 2008, 33:198-213.
24. Zeng H., Schimpf B.A., Rohde A.D., Pavlova M.N., Gragerov A., Bergmann J.E. Thyrotropin-releasing hormone receptor 1-deficient mice display increased depression and anxiety-like behavior. Mol. Endocrinol. 2007, 21:2795-2804.
25. Reny-Palasse V., Constans M., Rips R. Potentiation by TRH of the effect of antidepressants in the forced-swimming test, involvement of dopaminergic and opioid systems. Br. J. Pharmacol. 1989, 97:197-205.
26. Marangell L.B., George M.S., Callahan A.M., et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch. Gen. Psychiatry 1997, 54:214-222.
27. Szuba M.P., Amsterdam J.D., Fernando A.T., Gary K.A., Whybrow P.C., Winokur A. Rapid antidepressant response after nocturnal TRH administration in patients with bipolar type I and bipolar type II major depression. J. Clin. Psychopharmacol. 2005, 25:325-330.
28. Horita A. An update on the CNS actions of TRH and its analogs. Life Sci. 1998, 62:1443-1448.
29. Blier P. Neurotransmitter targeting in the treatment of depression. J. Clin. Psychiatry 2013, 74:19-24.
30. Gainetdinov R.R., Wetsel W.C., Jones S.R., Levin E.D., Jaber M., Caron M.G. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science 1999, 283:397-401.
31. Mann J.J. The serotonergic system in mood disorders and suicidal behaviour. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2013, 368:20120537.
32. Rodgers R.J., Nikulina E.M., Cole J.C. Dopamine D1 and D2 receptor ligands modulate the behaviour of mice in the elevated plus-maze. Pharmacol. Biochem. Behav. 1994, 49:985-995.
33. Heal D.J., Stoodley N., Elliott J.M., Marsden C.A., Bennett G.W., Youdim M.B. Behavioural and biochemical evidence for the release of noradrenaline in mouse brain by TRH and some of its biologically stable analogues. Neuropharmacology 1987, 26:313-322.
34. Vogel R.A., Cooper B.R., Barlow T.S., Prange A.J., Mueller R.A., Breese G.R. Effects of thyrotropin-releasing hormone on locomotor activity, operant performance and ingestive behaviour. J. Pharmacol. Exp. Ther. 1979, 208:161-168.
35. Itoh Y., Ogasawara T., Yamazaki A., Ukai Y., Miura A., Kimura K. Enhancement of noradrenaline release from rat frontal cortex by thyrotropin releasing hormone and its analog, (3R,6R)-6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinami de, as studied by intracerebral microdialysis. J. Pharmacol. Exp. Ther. 1994, 268:255-261.
36. Cecchi M., Khoshbouei H., Javors M., Morilak D.A. Modulatory effects of norepinephrine in the lateral bed nucleus of the stria terminalis on behavioral and neuroendocrine responses to acute stress. Neuroscience 2002, 112:13-21.
37. Ragan C.M., Lonstein J.S. Differential postpartum sensitivity to the anxiety-modulating effects of offspring contact is associated with innate anxiety and brainstem levels of dopamine beta-hydroxylase in female laboratory rats. Neuroscience 2014, 256:433-444.
38. Oropeza V.C., Page M.E., Van Bockstaele E.J. Systemic administration of WIN 55,212-2 increases norepinephrine release in the rat frontal cortex. Brain Res. 2005, 1046:45-54.
39. Khan A.S., Fiorotto M.L., Cummings K.K., Pope M.A., Brown P.A., Draghia-Akli R. Maternal GHRH plasmid administration changes pituitary cell lineage and improves progeny growth of pigs. Am. J. Physiol. Endocrinol. Metab. 2003, 285:224-231.
40. Kinney B.A., Coschigano K.T., Kopchick J.J., Steger R.W., Bartke A. Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiol. Behav. 2001, 72:653-660.
41. Recinella L., Shohreh R., Salvatori R., Orlando G., Vacca M., Brunetti L. Effects of isolated GH deficiency on adipose tissue, feeding and adipokines in mice. Growth Horm. IGF Res. 2013, 23:237-242.
42. Rodriguez-Pacheco F., Martinez-Fuentes A.J., Tovar S., et al. Regulation of pituitary cell function by adiponectin. Endocrinology 2007, 148:401-410.